Search
Ascendis Pharma A/S
ASNDAdd to Watchlist
243.910USD
-7.160-2.85%
Close 07-31 16:00（ET）Quotes delayed by 15 min
15.12BMarket Cap
35.15P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Ascendis Pharma A/S is 9.00, ranking 16 out of 385 in the Biotechnology & Medical Research industry. The average price target is 254.00, with a high of 325.00 and a low of 220.00.
Analyst Rating
Based on
20
analysts
Strong Buy
Current Rating
310.417
Target Price
+23.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Ascendis Pharma A/S
ASND
20
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Ascendis Pharma A/S's expected revenue for the next quarter?
Ascendis Pharma A/S's expected revenue is 382.19M.
What is Ascendis Pharma A/S's price target?
Analysts forecast that Ascendis Pharma A/S's price target is USD 254.00, with the highest forecast at USD 325.00 and the lowest forecast at USD 220.00.
How have Ascendis Pharma A/SASND's recent earnings per share performed?
The market expectation was USD 11.79, while Ascendis Pharma A/SASND's earnings per share (EPS) for the previous quarter was USD -0.64. EPS for the next quarter is expected at USD 1.59.
What is the analyst rating for Ascendis Pharma A/S?
Based on the ratings of Ascendis Pharma A/S's stock from 20 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.